Hypoglycemic Drugs Market, by Drug Class (Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones, Dipeptidyl peptidase-4 (DPP-4) inhibitors, and Glucagon), by Route of Administration (Oral, Injectable and Nasal), by Distribution Chan

Hypoglycemic Drugs Market, by Drug Class (Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones, Dipeptidyl peptidase-4 (DPP-4) inhibitors, and Glucagon), by Route of Administration (Oral, Injectable and Nasal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.

Market Dynamics

Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014–2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.

Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.

Key features of the study:

• This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global hypoglycemic drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market

Detailed Segmentation:

• Global Hypoglycemic Drugs Market, By Drug Class:
• Sulphonylureas
• Biguanides
• Alpha-glucosidase inhibitors
• Thiazolidinediones (Glitazones)
• Dipeptidyl peptidase-4 (DPP-4) inhibitors
• Glucagon
• Global Hypoglycemic Drugs Market, By Route of Administration:
• Oral
• Injectable
• Nasal
• Global Hypoglycemic Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Hypoglycemic Drugs Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Eli Lilly & Company*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Boehringer Ingelheim GmbH
• Vistin Pharma AS
• Janssen Pharmaceuticals NV
• Sanofi
• Astellas Pharma Inc.
• AstraZeneca plc.
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Teva Pharmaceuticals Pvt Ltd.
• Sun Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.